Published in Antimicrob Agents Chemother on April 01, 1972
Low-affinity penicillin-binding protein associated with beta-lactam resistance in Staphylococcus aureus. J Bacteriol (1984) 14.64
beta-Lactamases in laboratory and clinical resistance. Clin Microbiol Rev (1995) 12.53
Synthesis of staphylococcal virulence factors is controlled by a regulatory RNA molecule. EMBO J (1993) 11.30
HR 756, a new cephalosporin active against gram-positive and gram-negative aerobic and anaerobic bacteria. Antimicrob Agents Chemother (1979) 10.60
Cefuroxime, a new cephalosporin antibiotic: activity in vitro. Antimicrob Agents Chemother (1976) 10.56
Antibacterial activity of a new 1-oxa cephalosporin compared with that of other beta-lactam compounds. Antimicrob Agents Chemother (1979) 10.01
Role of an altered penicillin-binding protein in methicillin- and cephem-resistant Staphylococcus aureus. Antimicrob Agents Chemother (1985) 8.66
Cloning, characterization, and sequencing of an accessory gene regulator (agr) in Staphylococcus aureus. J Bacteriol (1988) 8.18
Expression of methicillin resistance in heterogeneous strains of Staphylococcus aureus. Antimicrob Agents Chemother (1986) 7.71
Comparative activity and beta-lactamase stability of cefoperazone, a piperazine cephalosporin. Antimicrob Agents Chemother (1979) 7.65
Regulation of exoprotein expression in Staphylococcus aureus by a locus (sar) distinct from agr. Proc Natl Acad Sci U S A (1992) 6.95
Virulence genes regulated at the transcriptional level by Ca2+ in Yersinia pestis include structural genes for outer membrane proteins. Infect Immun (1986) 6.92
High-level tetracycline resistance in Neisseria gonorrhoeae is result of acquisition of streptococcal tetM determinant. Antimicrob Agents Chemother (1986) 6.34
Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J Clin Microbiol (1998) 6.26
Cell density control of staphylococcal virulence mediated by an octapeptide pheromone. Proc Natl Acad Sci U S A (1995) 6.13
Iron regulation of Shiga-like toxin expression in Escherichia coli is mediated by the fur locus. J Bacteriol (1987) 6.13
Novel plasmid-mediated beta-lactamase (MIR-1) conferring resistance to oxyimino- and alpha-methoxy beta-lactams in clinical isolates of Klebsiella pneumoniae. Antimicrob Agents Chemother (1990) 6.11
The role of beta-lactamase in staphylococcal resistance to penicillinase-resistant penicillins and cephalosporins. J Clin Microbiol (1986) 6.00
Multiple changes of penicillin-binding proteins in penicillin-resistant clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother (1980) 5.12
Outer membrane permeability in Pseudomonas aeruginosa: comparison of a wild-type with an antibiotic-supersusceptible mutant. Antimicrob Agents Chemother (1982) 4.98
HR 756, a highly active cephalosporin: comparison with cefazolin and carbenicillin. Antimicrob Agents Chemother (1978) 4.74
Formation of beta-lactamase in Bacteroides fragilis: cell-bound and extracellular activity. Antimicrob Agents Chemother (1976) 4.64
LY127935, a novel oxa-beta-lactam: an in vitro comparison with other beta-lactam antibiotics. Antimicrob Agents Chemother (1979) 4.52
Identification of a streptococcal penicillin-binding protein that reacts very slowly with penicillin. J Bacteriol (1983) 4.42
Clavulanic acid, a novel inhibitor of beta-lactamases. Antimicrob Agents Chemother (1978) 4.27
Characterization of non-beta-lactamase-mediated ampicillin resistance in Haemophilus influenzae. Antimicrob Agents Chemother (1984) 4.25
Sequencing the gene for an imipenem-cefoxitin-hydrolyzing enzyme (CfiA) from Bacteroides fragilis TAL2480 reveals strong similarity between CfiA and Bacillus cereus beta-lactamase II. J Bacteriol (1990) 4.24
Evolution of extended-spectrum beta-lactam resistance (SHV-8) in a strain of Escherichia coli during multiple episodes of bacteremia. Antimicrob Agents Chemother (1997) 4.20
The Escherichia coli K-12 "wild types" W3110 and MG1655 have an rph frameshift mutation that leads to pyrimidine starvation due to low pyrE expression levels. J Bacteriol (1993) 4.10
Plasmid-mediated beta-lactamase production in Neisseria gonorrhoeae. Antimicrob Agents Chemother (1977) 4.02
Types of beta-lactamase determined by plasmids in gram-negative bacteria. J Bacteriol (1979) 4.01
Regulation of penicillin-binding protein activity: description of a methicillin-inducible penicillin-binding protein in Staphylococcus aureus. Antimicrob Agents Chemother (1985) 3.98
Novel cassette-based shuttle vector system for gram-positive bacteria. Appl Environ Microbiol (2004) 3.97
Permeability of Pseudomonas aeruginosa outer membrane to hydrophilic solutes. J Bacteriol (1982) 3.94
Genetic analysis of the low calcium response in Yersinia pestis mu d1(Ap lac) insertion mutants. J Bacteriol (1984) 3.90
Beta-lactamase-mediated imipenem resistance in Bacteroides fragilis. Antimicrob Agents Chemother (1986) 3.87
Molecular characterization of two beta-lactamase-specifying plasmids isolated from Neisseria gonorrhoeae. J Bacteriol (1977) 3.76
Survey of methicillin-resistant clinical strains of coagulase-negative staphylococci for mecA gene distribution. Antimicrob Agents Chemother (1992) 3.73
Exfoliatin-producing strains define a fourth agr specificity group in Staphylococcus aureus. J Bacteriol (2000) 3.70
Activity of azlocillin and mezlocillin against gram-negative organisms: comparison with other penicillins. Antimicrob Agents Chemother (1978) 3.68
GR-20263: a new aminothiazolyl cephalosporin with high activity against Pseudomonas and Enterobacteriaceae. Antimicrob Agents Chemother (1980) 3.61
Antibacterial activity of cefuroxime, a new cephalosporin antibiotic, compared with that of cephaloridine, cephalothin, and cefamandole. Antimicrob Agents Chemother (1976) 3.55
Antibacterial activity of ceftriaxone (Ro 13-9904), a beta-lactamase-stable cephalosporin. Antimicrob Agents Chemother (1981) 3.50
LY-127935: a novel beta-lactam antibiotic with unusual antibacterial activity. Antimicrob Agents Chemother (1979) 3.49
Chancroid and Haemophilus ducreyi. Clin Microbiol Rev (1989) 3.41
Isolation and identification of Haemophilus ducreyi in a clinical study. J Clin Microbiol (1980) 3.40
Increased amounts of a novel penicillin-binding protein in a strain of methicillin-resistant Staphylococcus aureus exposed to nafcillin. J Clin Invest (1985) 3.35
Five novel plasmid-determined beta-lactamases. Antimicrob Agents Chemother (1985) 3.34
Altered penicillin-binding proteins in methicillin-resistant strains of Staphylococcus aureus. Antimicrob Agents Chemother (1981) 3.29
Antimicrobial susceptibility of Haemophilus ducreyi. Antimicrob Agents Chemother (1978) 3.23
Chromogenic cephalosporin spot test to detect beta-lactamase in clinically significant bacteria. J Clin Microbiol (1979) 3.17
Antibacterial activity of ceftizoxime, a beta-lactamase-stable cephalosporin. Antimicrob Agents Chemother (1980) 3.14
Rapid detection of ampicillin-resistant Haemophilus influenzae and their susceptibility to sixteen antibiotics. Antimicrob Agents Chemother (1975) 3.09
Production of low-affinity penicillin-binding protein by low- and high-resistance groups of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (1987) 3.07
In vitro activity of N-formimidoyl thienamycin in comparison with cefotaxime, moxalactam, and ceftazidime. Antimicrob Agents Chemother (1981) 3.05
Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc Natl Acad Sci U S A (2000) 3.04
Pseudomonas aeruginosa outer membrane permeability: isolation of a porin protein F-deficient mutant. J Bacteriol (1983) 2.98
Role of penicillinase plasmids in the stability of the mecA gene in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (1990) 2.93
Competition of beta-lactam antibiotics for the penicillin-binding proteins of Pseudomonas aeruginosa, Enterobacter cloacae, Klebsiella aerogenes, Proteus rettgeri, and Escherichia coli: comparison with antibacterial activity and effects upon bacterial morphology. Antimicrob Agents Chemother (1979) 2.89
Growth phenotypes of Pseudomonas aeruginosa lasR mutants adapted to the airways of cystic fibrosis patients. Mol Microbiol (2007) 2.87
Increase in antibiotic resistance in Haemophilus influenzae in the United Kingdom since 1977: report of study group. Br Med J (Clin Res Ed) (1982) 2.78
Bronchopulmonary infection due to Branhamella catarrhalis: 11 cases assessed by transtracheal puncture. Br Med J (1978) 2.77
Inactivation of cephalosporins by Bacteroides. Antimicrob Agents Chemother (1979) 2.75
Molecular cloning and expression of Bacillus licheniformis beta-lactamase gene in Escherichia coli and Bacillus subtilis. J Bacteriol (1981) 2.75
Expression of a Streptococcus mutans glucosyltransferase gene in Escherichia coli. J Bacteriol (1983) 2.74
CP-45,899 in combination with penicillin or ampicillin against penicillin-resistant Staphylococcus, Haemophilus influenzae, and Bacteroides. Antimicrob Agents Chemother (1980) 2.74
In vitro evaluation of HR810, a new wide-spectrum aminothiazolyl alpha-methoxyimino cephalosporin. Antimicrob Agents Chemother (1984) 2.73
Ro 13-9904, a long-acting broad-spectrum cephalosporin: in vitro and in vivo studies. Antimicrob Agents Chemother (1980) 2.71
Resistance to beta-lactam antibiotics in Streptococcus faecium. Antimicrob Agents Chemother (1982) 2.68
Role of the ftsA gene product in control of Escherichia coli cell division. J Bacteriol (1979) 2.66
Increased production of penicillin-binding protein 2, increased detection of other penicillin-binding proteins, and decreased coagulase activity associated with glycopeptide resistance in Staphylococcus aureus. Antimicrob Agents Chemother (1997) 2.65
Mechanism of resistance of an ampicillin-resistant, beta-lactamase-negative clinical isolate of Haemophilus influenzae type b to beta-lactam antibiotics. Antimicrob Agents Chemother (1984) 2.65
Cefoxitin inactivation by Bacteroides fragilis. Antimicrob Agents Chemother (1983) 2.64
Conjugative transfer of multiple antibiotic resistance markers in Streptococcus pneumoniae. J Bacteriol (1980) 2.63
Genotypic identification of methicillin-resistant coagulase-negative staphylococci by polymerase chain reaction. Antimicrob Agents Chemother (1991) 2.61
Molecular cloning and nucleotide sequence of the type I beta-lactamase gene from Bacillus cereus. Nucleic Acids Res (1983) 2.61
Negative control of cell division by mreB, a gene that functions in determining the rod shape of Escherichia coli cells. J Bacteriol (1989) 2.60
Biochemical characteristics of Haemophilus influenzae in relationship to source of isolation and antibiotic resistance. J Clin Microbiol (1978) 2.60
In vitro study of clavulanic acid in combination with penicillin, amoxycillin, and carbenicillin. Antimicrob Agents Chemother (1978) 2.58
Comparison of in vitro activity of GR 20263, a novel cephalosporin derivative, with activities of other beta-lactam compounds. Antimicrob Agents Chemother (1980) 2.51
Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined beta-lactamase-producing aerobic gram-negative bacilli. Antimicrob Agents Chemother (1986) 2.48
Comparative in vitro activity of 1-oxa-beta-lactam (LY127935) and cefoperazone with other beta-lactam antibiotics against anaerobic bacteria. Antimicrob Agents Chemother (1980) 2.47
In vitro antimicrobial activity evaluation of cefodizime (HR221), a new semisynthetic cephalosporin. Antimicrob Agents Chemother (1981) 2.45
Permeability barrier to hydrophilic solutes in Mycobacterium chelonei. J Bacteriol (1990) 2.44
Identification of an iron-regulated virulence determinant in Vibrio cholerae, using TnphoA mutagenesis. Infect Immun (1990) 2.44
Transcriptional and posttranscriptional regulation of manganese superoxide dismutase biosynthesis in Escherichia coli, studied with operon and protein fusions. J Bacteriol (1988) 2.43
Role of porin proteins OmpF and OmpC in the permeation of beta-lactams. Antimicrob Agents Chemother (1982) 2.43
Gonococcal resistance to beta-lactams and tetracycline involves mutation in loop 3 of the porin encoded at the penB locus. Antimicrob Agents Chemother (1998) 2.41
Failure to detect ampicillin-resistant, non-beta-lactamase-producing Haemophilus influenzae by standard disk susceptibility testing. Antimicrob Agents Chemother (1986) 2.38
Genetic and biochemical analysis of a novel Ambler class A beta-lactamase responsible for cefoxitin resistance in Bacteroides species. Antimicrob Agents Chemother (1993) 2.35
In vitro antimicrobial production of beta-lactamases, aminoglycoside-modifying enzymes, and chloramphenicol acetyltransferase by and susceptibility of clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother (1993) 2.34
Antibiotic susceptibility of Neisseria gonorrhoeae strains from Europe and Africa. Antimicrob Agents Chemother (1979) 2.31
In vitro studies of plasmid-mediated penicillinase from Streptococcus faecalis suggest a staphylococcal origin. J Clin Invest (1986) 2.31
Emergence of resistance after spectinomycin treatment for gonorrhoea due to beta-lactamase producing strain of Neisseria gonorrhoeae. Br Med J (Clin Res Ed) (1982) 2.29
Properties of the beta-lactamase specified by the Pseudomonas plasmid RPL11. J Bacteriol (1977) 2.29
Nucleotide sequence and expression of the beta-lactamase gene from Staphylococcus aureus plasmid pI258 in Escherichia coli, Bacillus subtilis, and Staphylococcus aureus. J Bacteriol (1987) 2.27
Antibacterial activity and beta-lactamase stability of ceftazidime, an aminothiazolyl cephalosporin potentially active against Pseudomonas aeruginosa. Antimicrob Agents Chemother (1982) 2.26
Nosocomial colonization and infection by Achromobacter xylosoxidans. J Clin Microbiol (1984) 2.24
Antimicrobial susceptibility patterns of common and unusual species of enterococci causing infections in the United States. Enterococcal Study Group. J Clin Microbiol (1992) 2.23
Use of genetic recombination as a reporter of gene expression. Proc Natl Acad Sci U S A (1994) 2.21
Protein measurement with the Folin phenol reagent. J Biol Chem (1951) 1743.91
Cephalosporinase and penicillinase activities of a beta-lactamase from Pseudomonas pyocyanea. Biochem J (1965) 12.54
A comparative study of eight distinct beta-lactamases synthesized by gram-negative bacteria. J Gen Microbiol (1970) 11.21
Chemical structure of bacterial penicillinases. Nature (1969) 8.63
Effects of beta-lactamase from gram-negative organisms on cephalosporins and penicillins. Antimicrob Agents Chemother (Bethesda) (1968) 8.23
Antimicrobial studies in vitro with CIBA 36278-Ba, a new cephalosporin derivative. Antimicrob Agents Chemother (Bethesda) (1970) 6.46
Comparative amino acid contents of purified beta-lactamases from enteric bacteria. FEBS Lett (1970) 6.15
[Dynamics of beta-lactamase-like activity of the kidneys of albino mice under conditions of staphylococcal infection and the action of penicillins]. Antibiotiki (1970) 5.75
The estimation of penicillins and penicillin destruction. J Pharm Pharmacol (1963) 5.66
Some cephalosporins in clinical use and their structure-activity relationships. Postgrad Med J (1970) 5.56
The fate of parenteral cephalothin and related antibiotics in the rat. The nature of a minor long-lived metabolite. J Antibiot (Tokyo) (1971) 5.43
The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med (1994) 27.68
Cefuroxime, a new cephalosporin antibiotic: activity in vitro. Antimicrob Agents Chemother (1976) 10.56
Effects of beta-lactamase from gram-negative organisms on cephalosporins and penicillins. Antimicrob Agents Chemother (Bethesda) (1968) 8.23
Cefuroxime - a new cephalosporin antibiotic. J Antibiot (Tokyo) (1976) 7.95
Ingestion of Campylobacter pyloridis causes gastritis and raised fasting gastric pH. Am J Gastroenterol (1987) 7.09
GR 20263, a new broad-spectrum cephalosporin with anti-pseudomonal activity. Antimicrob Agents Chemother (1980) 6.77
Is informed consent always necessary for randomized, controlled trials? . N Engl J Med (1999) 6.32
Some cephalosporins in clinical use and their structure-activity relationships. Postgrad Med J (1970) 5.56
Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia (2003) 4.33
Uses of barium meal examination in dyspeptic patients under 50. Br Med J (1977) 3.82
Laoratory appraisal of cephalexin. Antimicrob Agents Chemother (Bethesda) (1968) 3.75
Inhibition of beta-lactamases by beta-lactam antibiotics. Antimicrob Agents Chemother (1972) 3.72
Description and classification of the newer cephalosporins and their relationships with the established compounds. J Antimicrob Chemother (1979) 3.47
Report of the American-European consensus conference on ARDS: definitions, mechanisms, relevant outcomes and clinical trial coordination. The Consensus Committee. Intensive Care Med (1994) 3.21
Pertussis is a frequent cause of prolonged cough illness in adults and adolescents. Clin Infect Dis (2001) 3.11
Beta-lactamase assays. Methods Enzymol (1975) 3.06
Has misdiagnosis of appendicitis decreased over time? A population-based analysis. JAMA (2001) 3.06
Comparison of assay techniques for beta-lactamase activity. Anal Biochem (1973) 2.96
R-factor mediated beta-lactamase production by Haemophilus influenzae. J Med Microbiol (1975) 2.75
Seroepidemiology of Campylobacter pyloridis. N Z Med J (1986) 2.52
A new approach to the study of serum concentrations of orally administered cephalexin. J Pharm Pharmacol (1971) 2.36
A pilot study of naltrexone-accelerated detoxification in opioid dependence. Med J Aust (1999) 2.13
Cutaneous malignant melanoma in Scotland: incidence, survival, and mortality, 1979-94. The Scottish Melanoma Group. BMJ (1997) 2.08
Report of the American-European Consensus conference on acute respiratory distress syndrome: definitions, mechanisms, relevant outcomes, and clinical trial coordination. Consensus Committee. J Crit Care (1994) 2.07
Rapid diagnosis of Campylobacter pyloridis infection. Lancet (1986) 2.03
Clear correlation of genotype with disease phenotype in very-long-chain acyl-CoA dehydrogenase deficiency. Am J Hum Genet (1999) 1.99
Fetal alcohol syndrome: a prospective national surveillance study. Arch Dis Child (2007) 1.98
The action of cephaloridine with cloxacillin or methicillin against beta-lactamase-producing gram-negative bacteria. J Gen Microbiol (1967) 1.89
Kinetics of the antibody response to tetanus-diphtheria-acellular pertussis vaccine in women of childbearing age and postpartum women. Clin Infect Dis (2011) 1.84
Ophthalmic survey of a diabetic clinic. I: Ocular findings. Br J Ophthalmol (1986) 1.80
Interventions for impetigo. Cochrane Database Syst Rev (2004) 1.78
Prevalence and predictors of disability in valued life activities among individuals with rheumatoid arthritis. Ann Rheum Dis (2005) 1.77
Community-acquired pneumonia: the annual cost to the National Health Service in the UK. Eur Respir J (1997) 1.75
Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J Immunol (2000) 1.74
Neonatal screening for medium-chain acyl-CoA dehydrogenase deficiency. Lancet (2001) 1.64
Bronchiectasis in Alaska Native children: causes and clinical courses. Pediatr Pulmonol (2000) 1.63
Inhibition of beta-lactamase decomposition of cephaloridine and cephalothin by other cephalosporins. Antimicrob Agents Chemother (Bethesda) (1966) 1.61
Venous and arterial gas embolism associated with positive pressure ventilation. Chest (1998) 1.52
Maintenance of lower proportions of (n - 6) eicosanoid precursors in phospholipids of human plasma in response to added dietary (n - 3) fatty acids. Biochim Biophys Acta (1992) 1.50
Binding of different forms of lipopolysaccharide and gene expression in bovine blood neutrophils. J Dairy Sci (2009) 1.48
A new cephalosporin with a dual mode of action. Antimicrob Agents Chemother (1976) 1.48
Temporal evolution in the management of acute ST elevation myocardial infarction: the seven-year GUSTO experience from canada and the united states. The North American GUSTO-I and GUSTO-III investigators. Can J Cardiol (2000) 1.47
A prospective randomised trial of absorbable versus non-absorbable sutures for wound closure after fasciectomy for Dupuytren's contracture. J Hand Surg Eur Vol (2009) 1.42
Myristoylated alanine-rich C kinase substrate (MARCKS) produces reversible inhibition of phospholipase C by sequestering phosphatidylinositol 4,5-bisphosphate in lateral domains. J Biol Chem (1996) 1.41
The mode of action of novobiocin. Prog Med Chem (1971) 1.37
Pharmacokinetics and systemic effects of inhaled fluticasone propionate in chronic obstructive pulmonary disease. Br J Clin Pharmacol (2003) 1.36
Correlation between hydrolysis of the -lactam bond of the cephalosporin nucleus and expulsion of the 3-substituent. J Bacteriol (1972) 1.32
Do managed clinical networks improve quality of diabetes care? Evidence from a retrospective mixed methods evaluation. Qual Saf Health Care (2009) 1.31
Ophthalmic survey of a diabetic clinic: II. Requirements for treatment of retinopathy. Br J Ophthalmol (1986) 1.27
Irreversible effects of serum proteins on beta-lactam antibiotics. Antimicrob Agents Chemother (1978) 1.25
Principal beta-lactamases responsible for resistance to beta-lactam antibiotics in urinary tract infections. Antimicrob Agents Chemother (1980) 1.25
Regulation of cellular antibody synthesis effect of adoptively transferred antibody-producing spleen cells on cellular antibody synthesis. J Immunol (1968) 1.19
Activation of ATP-ubiquitin-dependent proteolysis in skeletal muscle in vivo and murine myoblasts in vitro by a proteolysis-inducing factor (PIF). Br J Cancer (2001) 1.18
Spironolactone impairs endothelial function and heart rate variability in patients with type 2 diabetes. Diabetologia (2004) 1.18
Clinically significant Streptococcus anginosus (Streptococcus milleri) infections: a review of 186 cases. N Z Med J (1988) 1.17
Cytochalasin D does not produce net depolymerization of actin filaments in HEp-2 cells. Nature (1980) 1.16
Microbiological assay of mixed cephalosporins. Antimicrob Agents Chemother (Bethesda) (1967) 1.16
Effects of monoclonal antibodies to the alpha and beta chains of the human lymphocyte function-associated (H-LFA-1) antigen on T lymphocyte functions. Eur J Immunol (1985) 1.16
The human muscle nicotinic acetylcholine receptor alpha-subunit exist as two isoforms: a novel exon. EMBO J (1990) 1.15
Membrane binding of phospholipases C-beta 1 and C-beta 2 is independent of phosphatidylinositol 4,5-bisphosphate and the alpha and beta gamma subunits of G proteins. Biochemistry (1996) 1.14
Sp1 binding is critical for promoter assembly and activation of the MCP-1 gene by tumor necrosis factor. J Biol Chem (2000) 1.13
A frameshift mutation in exon 28 of the OPA1 gene explains the high prevalence of dominant optic atrophy in the Danish population: evidence for a founder effect. Hum Genet (2001) 1.12
Quantitative effects of dietary polyunsaturated fats on the composition of fatty acids in rat tissues. Lipids (1990) 1.11
Identification of two binding sites for wheat-germ agglutinin on polylactosamine-type oligosaccharides. Biochem J (1985) 1.11
Arrhythmogenicity of IgG and anti-52-kD SSA/Ro affinity-purified antibodies from mothers of children with congenital heart block. Circ Res (1997) 1.09
Pneumocystis colonisation is common among hospitalised HIV infected patients with non-Pneumocystis pneumonia. Thorax (2007) 1.08
Confirmation of the novel association at the BTNL2 locus with ulcerative colitis. Tissue Antigens (2009) 1.06
Pre-engraftment syndrome after myeloablative dual umbilical cord blood transplantation: risk factors and response to treatment. Bone Marrow Transplant (2013) 1.04
Presence of the T-cell activation marker OX-40 on tumor infiltrating lymphocytes and draining lymph node cells from patients with melanoma and head and neck cancers. Am J Surg (1997) 1.03
Long-term results, hemodynamics, and complications after combined heart and lung transplantation. Circulation (1985) 1.03
SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br J Dermatol (2001) 1.03
The isolation and characterization of a clonally related series of murine retrovirus-infected mouse cells. J Gen Virol (1980) 1.01
Cytokine augmentation of HIV-1 LTR-driven gene expression in neural cells. AIDS Res Hum Retroviruses (1992) 1.01
Classification of cephalosporins by their antibacterial activity and pharmacokinetic properties. J Antimicrob Chemother (1975) 1.00
Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev (2005) 1.00
Campylobacter pyloridis infection in Auckland patients with gastritis. N Z Med J (1986) 1.00
Computed tomography, ultrasound, and cholestatic jaundice. Gut (1978) 1.00
Assessment of a programme to screen the newborn for congenital hypothyroidism. Community Med (1979) 0.99
A low-temperature-responsive translation elongation factor 1 alpha from barley (Hordeum vulgare L.). Plant Mol Biol (1993) 0.99
Drug use behaviors among Asian drug users in San Francisco. Addict Behav (2000) 0.99
Screening for medium chain acyl-CoA dehydrogenase deficiency has still not been evaluated. . BMJ (2001) 0.98
Fecal leukocytes in stool specimens submitted for Clostridium difficile toxin assay. Diagn Microbiol Infect Dis (1993) 0.98
Vertebral column injuries and lap-shoulder belts. J Trauma (1995) 0.98
Progressive pulmonary insufficiency and other pulmonary complications of thermal injury. J Trauma (1975) 0.97
Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients. Arch Dis Child (2003) 0.96
Low tidal volume ventilation is associated with reduced mortality in HIV-infected patients with acute lung injury. Thorax (2008) 0.96
B-type natriuretic peptide can detect silent myocardial ischaemia in asymptomatic type 2 diabetes. Heart (2005) 0.96
Tumour necrosis factor alpha and interleukin-1 beta induce specific subunits of NFKB to bind the HIV-1 enhancer: characterisation of transcription factors controlling human immunodeficiency virus type 1 gene expression in neural cells. Biochem Biophys Res Commun (1994) 0.95
Heart transplantation for Barth syndrome. Pediatr Cardiol (1997) 0.95